Challenge and promise: Roles for Livin in progression and therapy of cancer

Molecular Cancer Therapeutics

Volumn 7, Issue 12, 2008, Pages 3661-3669

  Wang, Ling ^a   Zhang, Qi ^a   Liu, Bin ^a   Han, Mei ^a   Shan, Baoen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CASPASE 3; CASPASE 7; CASPASE 9; LIVIN; LIVIN ALPHA; LIVIN BETA; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SHORT SURVEY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; PROGNOSIS; PROTEIN BIOSYNTHESIS; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION, GENETIC;

EID: 57749116568     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0480     Document Type: Short Survey

References (75)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
2. Horvitz HR. Worms, life, and death (Nobel Lecture). Chembiochem 2003;4:697-711.
3. Abrams JM. An emerging blueprint for apoptosis in Drosophila. Trends Cell Biol 1999;9:435-40.
4. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15:2922-33.
5. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999;13:239-52.
6. Miller LK. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol 1999;9:323-8.
7. Richter BW, Duckett CS. The IAP proteins: caspase inhibitors and beyond. Sci STKE 2000;8:PE1.
8. Deveraux QL, Stennicke HR, Salvesen GS, Reed JC. Endogenous inhibitors of caspases. J Clin Immunol 1999;19:388-98.
9. Bergmann A, Yang AY, Srivastava M. Regulators of IAP function: coming to grips with the grim reaper. Curr Opin Cell Biol 2003;15:717-24.
10. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. MLIAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000;10:1359-66.
11. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001;495:56-60.
12. Hinds MG, Norton RS, Vaux DL, Day CL. Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. Nat Struct Biol 1999;6:648-51.
13. Lin JH, Deng G, Huang Q, Morser J. KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun 2000; 279:820-31.
14. Borden KL. RING domains: master builders of molecular scaffolds? J Mol Biol 2000;295:1103-12.
15. Silke J, Kratina T, Chu D, et al. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc Natl Acad Sci U S A 2005;102:16182-7.
16. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000;288:874-7.
17. Ma L, Huang Y, Song Z, et al. Livin promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway. Cell Death Differ 2006;13:2079-88.
18. Ka H, Hunt JS. Temporal and spatial patterns of expression of inhibitors of apoptosis in human placentas. Am J Pathol 2003;163:413-22.
19. Gazzaniga P, Gradilone A, Giuliani L, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003;14:85-90.
20. Crnković-Mertens I, Semzow J, Hoppe-Seyler F, Butz K. Isoform-specific silencing of the Livin gene by RNA interference defines Livin h as key mediator of apoptosis inhibition in HeLa cells. J Mol Med 2006;84:232-40.
21. Nachmias B, Mizrahi S, Elmalech M, et al. Manipulation of NK cytotoxicity by the IAP family member Livin. Eur J Immunol 2007;37:3467-76.
22. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997;91:443-6.
23. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-67.
24. Reed JC. Cytochrome c: can't live with it-can't live without it. Cell 1997;91:559-62.
25. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12.
26. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBOJ 1997;16:6914-25.
27. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBOJ 1998;17:2215-23.
28. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300-4.
29. Sun C, Cai M, Gunasekera AH, et al. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 1999;401:818-22.
30. Chai J, Shiozaki E, Srinivasula SM, et al. Structural basis of caspase-7 inhibition by XIAP. Cell 2001;104:769-80.
31. Sun C, Cai M, Meadows RP, et al. NMR structure and mutagenesis of the third BIR domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 2000;275:33777-81.
32. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001;276:3238-46.
33. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBOJ 2006;7:988-94.
34. Vucic D, Franklin MC, Wallweber HJA, et al. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J 2005;385:11-20.
35. Shin H, Renatus M, Eckelman BP, Nunes VA, Sampaio CA, Salvesen GS. The BIR domain of IAP-like protein 2 is conformationally unstable: implications for caspase inhibition. Biochem J 2005;385:1-10.
36. Wilkinson JC, Wilkinson AS, Scott FL, Csomos RA, Salvesen GS, Duckett CS. Neutralization of Smac/DIABLOby IAPs: a caspase-independent mechanism for apoptotic inhibition. J Biol Chem 2004;279:51082-90.
37. Sanna MG, Duckett CS, Richter BW, Thompson CB, Ulevitch RJ. Selective activation of JNK1 is necessary for the anti-apoptotic activity of hILP. Proc Natl Acad Sci U S A 1998;95:6015-20.
38. Sanna MG, da Silva Correia J, Ducrey O, et al. IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol 2002;22:1754-66.
39. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003;22:7218-21.
40. Yuan D, Liu L, Gu D. Transcriptional regulation of livin by β-catenin/ TCF signaling in human lung cancer cell lines. Mol Cell Biochem 2007;306:171-8.
41. Nachmias B, Ashhab Y, Bucholtz V, et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res 2003;63:6340-9.
42. Nachmias B, Lazar I, Elmalech M, et al. Subcellular localization determines the delicate balance between the anti- and pro-apoptotic activity of Livin. Apoptosis 2007;12:1129-42.
43. Harvey AJ, Soliman H, Kaiser WJ, Miller LK. Anti- and pro-apoptotic activities of baculovirus and Drosophila IAPs in an insect cell line. Cell Death Differ 1997;4:733-44.
44. Kim DK, Alvarado CS, Abramowsky CR, et al. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Dev Pathol 2005;8:621-9.
45. Kempkensteffen C, Hinz S, Christoph F, et al. Expression of the apoptosis inhibitor Livin in renal cell carcinomas: correlations with pathology and outcome. Tumour Biol 2007;28:132-8.
46. Wagener N, Crnković-Mertens I, Vetter C, et al. Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney. Br J Cancer 2007;97:1271-6.
47. Nedelcu T, Kubista B, Koller A, et al. Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol 2008;134:237-44.
48. Choi J, Hwang YK, Sung KW, et al. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 2007;109:471-7.
49. Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003;9:2826-36.
50. Tu SP, Jiang XH, Lin MC, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003;63:7724-32.
51. Xia C, Xu Z, Yuan X, et al. Induction of apoptosis in mesothelioma cells by anti-survivin oligonucleotides. Mol Cancer Ther 2002;1:687-94.
52. Puri N, Eller MS, Byers HR, Dykstra S, Kubera J, Gilchrest BA. Telomere-based DNA damage responses: a new approach to melanoma. FASEB J 2004;18:1373-81.
53. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 2005;12:217-27.
54. Chang H. RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research. Cancer Gene Ther 2007;14:677-85.
55. Crnkovic-Mertens I, Hoppe-Seyler F, Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the Livin/ML-IAP/KIAP gene. Oncogene 2003;22:8330-6.
56. Crnković-Mertens I, Wagener N, Semzow J, et al. Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci 2007;64:1137-44.
57. Crnković-Mertens I, Muley T, Meister M, et al. The anti-apoptotic Livin gene is an important determinant for the apoptotic resistance of nonsmall cell lung cancer cells. Lung Cancer 2006;54:135-42.
58. Alvarez-Salas LM, DiPaolo JA. Molecular approaches to cervical cancer therapy. Curr Drug Discov Technol 2007;4:208-19.
59. Pirollo KF, Chang EH. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 2008;68:1247-50.
60. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85.
61. Franklin MC, Kadkhodayan S, Ackerly H, et al. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (MLIAP). Biochemistry 2003;42:8223-31.
62. Nikolovska-Coleska Z, Meagher JL, Jiang S, et al. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Anal Biochem 2008;374:87-98.
63. Vucic D, Deshayes K, Ackerly H, et al. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J Biol Chem 2002;277:12275-9.
64. Allen SD, Rawale SV, Whitacre CC, Kaumaya PT. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. J Pept Res 2005;65:591.
65. Li L, Thomas RM, Suzuki H, et al. A small molecule smac mimic potentiates TRAIL- and TNF-α-mediated cell death. Science 2004;305:1471-4.
66. Zobel K, Wang L, Varfolomeev E, et al. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 2006;1:525-33.
67. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-90.
68. Huang Y, Lu M, Wu H. Antagonizing XIAP-mediated caspase-3 inhibition. Achilles' heel of cancers? Cancer Cell 2004;5:1-2.
69. Yagihashi A, Asanuma K, Tsuji N, et al. Detection of anti-Livin antibody in gastrointestinal cancer patients. Clin Chem 2003;49:1206-8.
70. Yagihashi A, Asanuma K, Kobayashi D, et al. Detection of autoantibodies to Livin and Survivin in sera from lung cancer patients. Lung Cancer 2005;48:217-21.
71. Yagihashi A, Ohmura T, Asanuma K, et al. Detection of autoantibodies to Survivin and Livin in sera from patients with breast cancer. Clin Chim Acta 2005;362:125-30.
72. Kitamura H, Honma I, Torigoe T, et al. Expression of Livin in renal cell carcinoma and detection of anti-Livin autoantibody in patients. Urology 2007;70:38-42.
73. Andersen MH, Reker S, Becker JC, thor Straten P. The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol 2004;122:392-9.
74. Andersen MH, Becher JC, Straten P. Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP. J Invest Dermatol 2004;122:1336-7.
75. Hariu H, Hirohashi Y, Torigoe T, et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res 2005;11:1000-9.